Spartan Micro, Inc.appointment of Donald Frei, M.D. to its Medical Advisory Board, where he will provide knowledge, insight and advice.

FREMONT, CALIFORNIA, UNITED STATES, July 25, 2017 /EINPresswire.com/ -- Spartan Micro, Inc., www.spartanmicro.com,a neurovascular device company, announced the appointment of Donald Frei, M.D. to its Medical Advisory Board. As part of our medical advisory board, Dr. Frei will provide knowledge, insight and advice regarding the following:

• Testing and feedback analysis of prototype and late stage proprietary technologies;
• Prioritizing and implementing product development and initiatives;
• Clinical activities; and,
• Long-range strategy for achieving its mission to create safer more effective neurovascular products.

“Dr. Frei’s addition to the Spartan Micro team increases the strength and knowledge base,” said Eric Stoppenhagen, Chief Executive Officer of Spartan Micro. “His service to SNIS brings an insight to a wide breath of varying practices in the neurointerventional field.”

“I am pleased to be mentoring Spartan Micro. The fast-paced environment where they take an idea to reality is very exciting.” said Dr. Frei. “I look forward to working with them on their next generation products.”
About Donald Frei, M.D.

Dr. Donald Frei received his medical degree from the University of Cincinnati School of Medicine in 1989 and completed a radiology residency at Tulane University, New Orleans, Louisiana in 1994. Additionally, he completed additional training in neuroradiology and endovascular surgical neuroradiology at Washington University/Mallinckrodt Institute of Radiology, St. Louis, Missouri in 1996.

Dr. Frei has been the director of Neuro-Interventional Surgery at Swedish Medical Center in Denver, Colorado since 2001. Swedish Medical Center was the first to be certified as a primary and comprehensive stroke center in Colorado. The 17th comprehensive stroke center certified in the USA. They treat ischemic and hemorrhagic stroke patients from a 6 state region in the western US, including: Colorado, Montana, Wyoming, Kansas, Nebraska and New Mexico. In 2016, we treated over 500 ischemic and hemorrhagic stroke patients.

Dr. Frei has been actively involved in ischemic and hemorrhagic stroke research for many years participating in many clinical trials, including: the ESCAPE trial, Proact I and Proact II, IMS 3, the SWIFT trial, Merci and MULTI Merci trials and the Penumbra Pivotal trial.

Dr. Frei has been on the board of directors for the Society of Neuro-Interventional Surgery (SNIS) for the past 10 years and has served as the President of SNIS since 2015. During his presidency, they have launched a national effort to elevate the systems of care for stroke patients nationwide, called Get Ahead of Stroke (www.getaheadofstroke.org).
Dr. Frei’s life mission: “To advance the care of neurovascular patients through cutting edge research, advocacy and excellent outcomes.”

About Spartan Micro, Inc.
Spartan Micro is a neurovascular medical device company based out of Fremont, California, USA. Its focus is research and development, production and sale of medical devices that will include coil embolics, over-the-wire, flow-guided microcatheters, guiding catheters, neurovascular stents and flow diversion stents.
Spartan Micro is currently developing mechanically detachable embolic coils for the occlusion of cerebral aneurysms. In addition to treating cerebral aneurysms, its coils will also be indicated for use in the peripheral vascular anatomy for occlusion or flow diversion for other vascular deformities.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction.

Investor Relations:
Spartan Micro, Inc.
Eric Stoppenhagen
Chief Executive Officer
Phone: 1- 512-270-8501
Email: info@SpartanMicro.com
www.spartanmicro.com

Eric Stoppenhagen
Spartan Micro, Inc.
9499030468
email us here